Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril

Nav

General Info

Geography

New Zealand (NZL)

Time period covered

01/1995 - 12/2000

Data type

Scientific literature

Keywords

Ischemic heart disease, Intracerebral hemorrhage, Subarachnoid hemorrhage, Ischemic stroke, Blood pressure

Citation

Authors

MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, Hart H, Scott J, White H

Journal

J Am Coll Cardiol

Volume

Issue

Pages

438–43

Publication year

2000

Suggested citation

MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, Hart H, Scott J, White H. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol. 2000; 36(2): 438–43.

GHDx Entry last modified on: Oct 8, 2022

Header sites

Search form

Main menu

Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril

Nav